Pharmacological inhibition of fatty acid synthase (FAS): A novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her‐2/neu (erbB‐2) oncogene‐induced malignant transformation

Molecular Carcinogenesis - Tập 41 Số 3 - Trang 164-178 - 2004
Javier A. Menéndez1, Inderjit Mehmi2, Vishal Verma2, Poh K. Teng2, Ruth Lupu2,3
1Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute, Evanston, Illinois 60201, USA.
2Department of Medicine, Breast Cancer Translational Research Laboratory, Evanston Northwestern Healthcare Research Institute, Evanston, Illinois
3Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago

Tóm tắt

AbstractWe designed our experiments to evaluate whether fatty acid synthase (FAS), a lipogenic enzyme linked to tumor virulence in population studies of human cancer, is necessary for the malignant transformation induced by Her‐2/neu (erbB‐2) oncogene, which is overexpressed not only in invasive breast cancer but also in premalignant atypical duct proliferations and in ductal carcinoma in situ of the breast. To avoid the genetic complexities associated with established breast cancer cell lines, we employed NIH‐3T3 mouse fibroblasts engineered to overexpress human Her‐2/neu coding sequence. NIH‐3T3/Her‐2 cells demonstrated a significant upregulation of FAS protein expression, which was dependent on the upstream activation of mitogen‐activated protein kinase and phosphatidylinositol 3′‐kinase/AKT pathways. Remarkably, pharmacological FAS blockade using the mycotoxin cerulenin or the novel small compound C75 completely suppressed the state of Her‐2/neu‐induced malignant transformation by inhibiting the ability of NIH‐3T3/Her‐2 cells to grow under either anchorage‐independent (i.e., to form colonies in soft agar) or low‐serum monolayer conditions. Moreover, NIH‐3T3/Her‐2 fibroblasts were up to three times more sensitive to chemical FAS inhibitors relative to untransformed controls as determined by MTT‐based cell viability assays. In addition, pharmacological FAS blockade preferentially induced apoptotic cell death of NIH‐3T3/Her‐2 fibroblasts, as determined by an ELISA for histone‐associated DNA fragments and by the terminal deoxynucleotidyltransferase (TdT)‐mediated nick end labeling assay (TUNEL). Interestingly, the degree of Her‐2/neu oncogene expression in a panel of breast cancer cell lines was predictive of sensitivity to chemical FAS inhibitors‐induced cytotoxicity, while low‐FAS expressing and chemical FAS inhibitors‐resistant MDA‐MB‐231 breast cancer cells became hypersensitive to FAS blockade when they were engineered to overexpress Her‐2/neu. Our observations strongly suggest that inhibition of FAS activity may provide a new molecular avenue for chemotherapeutic prevention and/or treatment of Her‐2/neu‐related breast carcinomas. © 2004 Wiley‐Liss, Inc.

Từ khóa


Tài liệu tham khảo

10.1016/S0899-9007(99)00266-X

10.1021/bi00437a001

10.1073/pnas.91.14.6379

Pizer ES, 1996, Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells, Cancer Res, 56, 2745

Pizer ES, 2000, Malonyl‐coenzyme A is a potential mediator of cytotoxicity induced by fatty‐acid synthase inhibition in human breast cancer cells and xenografts, Cancer Res, 60, 213

10.1073/pnas.97.7.3450

Zhou W, 2003, Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells, Cancer Res, 63, 7330

10.1002/pros.1052

10.1016/S0090-4295(95)96904-7

10.1054/bjoc.2001.1816

10.1046/j.1365-2559.2002.01289.x

10.1159/000064636

10.1002/(SICI)1097-0347(199907)21:4<325::AID-HED6>3.0.CO;2-P

Rashid A, 1997, Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia, Am J Pathol, 150, 201

Visca P, 1999, Immunohistochemical expression of fatty acid synthase, apoptotic‐regulating genes, proliferating factors, and ras protein product in colorectal adenomas, carcinomas, and adjacent nonneoplastic mucosa, Clin Cancer Res, 5, 4111

Milgraum LZ, 1997, Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma, Clin Cancer Res, 3, 2115

10.1309/5Y2L-CDCK-YB55-KDK6

DiGiovanna MP, 2002, Active signaling by HER‐2/neu in a subpopulation of HER‐2/neu‐overexpressing ductal carcinoma in situ: Clinicopathological correlates, Cancer Res, 62, 6667

10.1038/modpathol.3880503

Hoque A, 2002, HER‐2/neu gene amplification in ductal carcinoma in situ of the breast, Cancer Epidemiol Biomarkers Prev, 11, 587

Kumar‐Sinha C, 2003, Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis, Cancer Res, 63, 132

Menendez JA, 2004, Novel signaling molecules implicated in tumor‐associated fatty acid synthase‐dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acid, p53‐p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF‐kappaB, Int J Oncol, 24, 591

10.1023/B:BREA.0000018409.59448.60

10.1128/MMBR.40.3.681-697.1976

10.1016/0006-291X(72)90397-X

10.1016/0005-2760(81)90118-1

10.1074/jbc.274.10.6031

10.1126/science.2885917

10.1073/pnas.84.20.7159

Yakes FM, 2002, Herceptin‐induced inhibition of phosphatidylinositol‐3 kinase and Akt Is required for antibody‐mediated effects on p27, cyclin D1, and antitumor action, Cancer Res, 62, 4132

10.1038/35052073

Kurokawa H, 2001, Inhibition of erbB (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer, Clin Cancer Res, 7, 4436s

Pizer ES, 1996, Fatty acid synthase (FAS): A target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells, Cancer Res, 56, 745

10.1093/emboj/19.13.3159

10.1016/0005-2744(81)90232-1

10.1016/0005-2760(82)90105-9

10.1073/pnas.0403390101

10.1006/bbrc.1993.2644

10.1006/excr.2002.5600

Van de Sande T, 2002, Role of the phosphatidylinositol 3′‐kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells, Cancer Res, 62, 642

10.1074/jbc.273.39.25420

10.1038/sj.onc.1203889

10.1006/excr.2000.5054

10.1016/S0014-4827(02)00023-X

10.1172/JCI1411

10.1074/jbc.274.50.35832

Kotzka J, 2000, Sterol regulatory element binding proteins (SREBP)‐1a and SREBP‐2 are linked to the MAP‐kinase cascade, J Lipid Res, 41, 99, 10.1016/S0022-2275(20)32079-4

10.1042/0264-6021:3490013

Ookhtens M, 1984, Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor, Am J Physiol, 247, R146

Sabine JR, 1967, Control of lipid metabolism in hepatomas: Insensitivity of rate of fatty acid and cholesterol synthesis by mouse hepatoma BW7756 to fasting and to feedback control, Cancer Res, 27, 793

10.1038/72294

Wang SC, 2000, Transcriptional targeting of the HER‐2/neu oncogene, Drugs Today (Barc), 36, 835, 10.1358/dot.2000.36.12.606053

10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H

10.1016/S0006-291X(03)00265-1

10.1038/42408

10.1083/jcb.147.2.447

10.1194/jlr.R200021-JLR200

10.1083/jcb.141.4.929

10.1002/(SICI)1097-0320(19980601)32:2<120::AID-CYTO7>3.0.CO;2-P

10.1242/jcs.00118

DiGiovanna MP, 1999, Principles and Practice of Oncology

DiGiovanna MP, 1999, Principles and Practice of Oncology

Menendez JA, 2004, Inhibition of tumor‐associated fatty acid synthase activity enhances vinorelbine (Navelbine®)‐induced cytotoxicity and apoptotic cell death in human breast cancer cells, Oncol Rep, 12, 411

Moasser MM, 2001, The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2‐driven signaling and suppresses the growth of HER2‐overexpressing tumor cells, Cancer Res, 61, 7184

Thông tin
Thông tin xuất bản

Molecular Carcinogenesis

Tập 41 Số 3

164-178

Thông tin tác giả